Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Synovial sarcoma is an aggressive soft tissue sarcoma, occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).
Features include: Synovial sarcoma.
Biomarker and diagnostic research for synovial sarcoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
37 clinical trials registered, 24 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 2 PHASE3, 8 PHASE2, 23 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07174427](https://clinicaltrials.gov/study/NCT07174427) |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 6:00 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma |
PHASE3 |
Takara Bio Inc. |
RECRUITING |
[NCT06946225](https://clinicaltrials.gov/study/NCT06946225) | ACTengine® IMA203 Combined With mRNA-4203 | PHASE1 | Immatics US, Inc. | RECRUITING |
[NCT07261657](https://clinicaltrials.gov/study/NCT07261657) | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | EARLY_PHASE1 | Seth Pollack | RECRUITING |
[NCT05296564](https://clinicaltrials.gov/study/NCT05296564) | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | PHASE1 | Hadassah Medical Organization | RECRUITING |
[NCT07173972](https://clinicaltrials.gov/study/NCT07173972) | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. | PHASE2 | Oslo University Hospital | RECRUITING |
240 publications have been identified in PubMed for synovial sarcoma. Research spans Case Report / Case Series (32%), Review / Meta-Analysis (19%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 76 | 32% |
Research summaries | 45 | 19% |
Laboratory research | 42 | 18% |
Disease patterns and progression | 24 | 10% |
Clinical study results | 22 | 9% |
New treatment approaches | 16 | 7% |
Testing and diagnosis research | 12 | 5% |
Other research | 3 | 1% |
Mangla A (2026). [PMID: 36508540](https://pubmed.ncbi.nlm.nih.gov/36508540/). *Unknown Journal*. [Other]
Morishita H (2026). [PMID: 41594241](https://pubmed.ncbi.nlm.nih.gov/41594241/). *Diagnostics (Basel)*. [Case Report / Case Series]
Gao T (2026). [PMID: 42084470](https://pubmed.ncbi.nlm.nih.gov/42084470/). *Genes Chromosomes Cancer*. [Review / Meta-Analysis]
Naik K (2026). [PMID: 41848419](https://pubmed.ncbi.nlm.nih.gov/41848419/). *Int J Surg Pathol*. [Case Report / Case Series]
Walker EA (2026). [PMID: 41706083](https://pubmed.ncbi.nlm.nih.gov/41706083/). *Skeletal Radiol*. [Review / Meta-Analysis]
Phillipow N (2026). [PMID: 41543754](https://pubmed.ncbi.nlm.nih.gov/41543754/). *Am J Dermatopathol*. [Case Report / Case Series]
Haj Khalaf MA (2026). [PMID: 42243856](https://pubmed.ncbi.nlm.nih.gov/42243856/). *J Cardiothorac Surg*. [Review / Meta-Analysis]
Burg D (2026). [PMID: 41930172](https://pubmed.ncbi.nlm.nih.gov/41930172/). *Oncol Res*. [Review / Meta-Analysis]
Aye J (2026). [PMID: 41451550](https://pubmed.ncbi.nlm.nih.gov/41451550/). *Current opinion in pediatrics*. [Review / Meta-Analysis]
Aizpuru M (2026). [PMID: 40639783](https://pubmed.ncbi.nlm.nih.gov/40639783/). *The Annals of thoracic surgery*. [Review / Meta-Analysis]
AI-curated news mentioning synovial sarcoma
Updated Aug 28, 2026
A case report details the occurrence of synovial sarcoma in the abdominal wall muscles, contributing to the understanding of this rare cancer's presentation. This report may aid in recognizing atypical manifestations of synovial sarcoma.
A recent case study highlights the diagnostic challenges and surgical approach for primary synovial sarcoma located in the posterior mediastinum. This research contributes to the understanding of this rare cancer type and its management.
A recent case report highlights the presence of a BRAF V600E mutation in synovial sarcoma, contributing to the understanding of this rare cancer's molecular profile. The literature review provides insights into potential therapeutic targets for future research.